Adaptive Cash And Short Term Investments from 2010 to 2025
| ADPT Stock | USD 8.40 0.65 8.39% |
Cash And Short Term Investments | First Reported 2018-12-31 | Previous Quarter 243.3 M | Current Value 222.3 M | Quarterly Volatility 160.9 M |
Check Adaptive Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptive Biotechnologies' main balance sheet or income statement drivers, such as Net Interest Income of 2.5 M, Interest Income of 7.6 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 4.69, Dividend Yield of 0.0 or PTB Ratio of 4.57. Adaptive financial statements analysis is a perfect complement when working with Adaptive Biotechnologies Valuation or Volatility modules.
Adaptive | Cash And Short Term Investments |
Latest Adaptive Biotechnologies' Cash And Short Term Investments Growth Pattern
Below is the plot of the Cash And Short Term Investments of Adaptive Biotechnologies Corp over the last few years. Short Term Investments is an account in the current assets section of Adaptive Biotechnologies balance sheet. This account contains Adaptive Biotechnologies investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Adaptive Biotechnologies Corp fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. Adaptive Biotechnologies' Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adaptive Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
| Cash And Short Term Investments | 10 Years Trend |
|
Cash And Short Term Investments |
| Timeline |
Adaptive Cash And Short Term Investments Regression Statistics
| Arithmetic Mean | 300,350,941 | |
| Geometric Mean | 267,560,145 | |
| Coefficient Of Variation | 54.57 | |
| Mean Deviation | 134,874,677 | |
| Median | 192,150,000 | |
| Standard Deviation | 163,903,309 | |
| Sample Variance | 26864.3T | |
| Range | 523.3M | |
| R-Value | 0.55 | |
| Mean Square Error | 19948.8T | |
| R-Squared | 0.31 | |
| Significance | 0.03 | |
| Slope | 19,072,700 | |
| Total Sum of Squares | 402964.4T |
Adaptive Cash And Short Term Investments History
About Adaptive Biotechnologies Financial Statements
Adaptive Biotechnologies shareholders use historical fundamental indicators, such as Cash And Short Term Investments, to determine how well the company is positioned to perform in the future. Although Adaptive Biotechnologies investors may analyze each financial statement separately, they are all interrelated. The changes in Adaptive Biotechnologies' assets and liabilities, for example, are also reflected in the revenues and expenses on on Adaptive Biotechnologies' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash And Short Term Investments | 222.3 M | 418.3 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.